Zheng J, Xiao T, Ye P, Miao D, Wu H
Department of Geriatric Cardiology, Chinese People's Liberation Army General Hospital, Beijing, China.
Braz J Med Biol Res. 2017 Aug 31;50(10):e6363. doi: 10.1590/1414-431X20176363.
This study aimed to test the effects of xuezhikang, a cholestin extract that contains statin-like components, on arterial stiffness in patients with essential hypertension. One hundred hypertensive patients from the Chinese PLA General Hospital were randomly allocated to receive xuezhikang (1200 mg/day, orally) or placebo (same capsules containing only pharmaceutical excipients). Physical examination outcomes, lipid profile, high sensitivity C-reactive protein (hs-CRP) levels, matrix metalloproteinases-9 (MMP-9) levels, and arterial outcomes, including stiffness parameter (β), pressure-strain elasticity modulus (Ep), arterial compliance (AC), augmentation index (AI), and one-point pulse wave velocity (PWVβ) were obtained at baseline and after 6 months of the intervention. Xuezhikang significantly reduced β (8.4±3.1 vs 6.8±2.1, P=0.007), Ep (122.8±43.9 vs 100.7±33.2, P=0.009), PWVβ (6.7±1.2 vs 6.1±1.0, P=0.013), low-density lipoprotein cholesterol (3.4±0.6 vs 2.9±0.5, P=0.001), hs-CRP [2.1 (0.4-10.0) vs 1.4 (0.3-4.1), P=0.020], and MMP-9 (17.2±2.4 vs 12.7±3.8, P <0.001) compared to baseline. The placebo had no effect on these parameters. The changes of PWVβ in the xuezhikang group was significantly associated with the changes of hs-CRP and MMP-9 (r=0.144, P=0.043; r=0.278, P=0.030, respectively) but not with lipid profile changes. Our research showed xuezhikang can improve the parameters of arterial stiffness in hypertensive patients, and its effect was independent of lipid lowering.
本研究旨在测试血脂康（一种含有他汀类成分的红曲提取物）对原发性高血压患者动脉僵硬度的影响。来自中国人民解放军总医院的100例高血压患者被随机分配接受血脂康（1200毫克/天，口服）或安慰剂（仅含药用辅料的相同胶囊）。在基线时以及干预6个月后，获取体格检查结果、血脂谱、高敏C反应蛋白（hs-CRP）水平、基质金属蛋白酶-9（MMP-9）水平以及动脉相关结果，包括僵硬度参数（β）、压力-应变弹性模量（Ep）、动脉顺应性（AC）、增强指数（AI）和单点脉搏波速度（PWVβ）。与基线相比，血脂康显著降低了β（8.4±3.1对6.8±2.1，P = 0.007）、Ep（122.8±43.9对100.7±33.2，P = 0.009）、PWVβ（6.7±1.2对6.1±1.0，P = 0.013）、低密度脂蛋白胆固醇（3.4±0.6对2.9±0.5，P = 0.001）、hs-CRP[2.1（0.4 - 10.0）对1.4（0.3 - 4.1），P = 0.020]以及MMP-9（17.2±2.4对12.7±3.8，P <0.001）。安慰剂对这些参数无影响。血脂康组中PWVβ的变化与hs-CRP和MMP-9的变化显著相关（分别为r = 0.144，P = 0.043；r = 0.278，P = 0.030），但与血脂谱变化无关。我们的研究表明，血脂康可改善高血压患者的动脉僵硬度参数，且其作用独立于降脂作用。
